AR032778A1 - Benzimidazoles sustituidos, y su utilizacion para la preparacion de medicamento - Google Patents
Benzimidazoles sustituidos, y su utilizacion para la preparacion de medicamentoInfo
- Publication number
- AR032778A1 AR032778A1 ARP010105612A ARP010105612A AR032778A1 AR 032778 A1 AR032778 A1 AR 032778A1 AR P010105612 A ARP010105612 A AR P010105612A AR P010105612 A ARP010105612 A AR P010105612A AR 032778 A1 AR032778 A1 AR 032778A1
- Authority
- AR
- Argentina
- Prior art keywords
- represent
- alkyl
- substituted
- unsubstituted
- fluorine
- Prior art date
Links
- 150000001556 benzimidazoles Chemical group 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 17
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 15
- 239000011737 fluorine Substances 0.000 abstract 14
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 12
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 1
- 101100114469 Arabidopsis thaliana COR27 gene Proteins 0.000 abstract 1
- 102000050381 Na+/H+ exchanger Human genes 0.000 abstract 1
- 108091006672 Sodium–hydrogen antiporter Proteins 0.000 abstract 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Benzimidazoles sustituidos que comprenden la formula (1), en la cual: R1 y R5, independientemente entre sí, representan F, Cl, Br, I, CN, alquilo C1-4, no sustituido o sustituido total o parcialmente por fluor; o R1 y R5 representan cicloalquilo C3-7, no sustituido o sustituido total o parcialmente por fluor; o R1 y R5 representan OH, O-alquilo C1-4, no sustituido o sustituido total o parcialmente por fluor; o R1 y R5 representan OCOR10, NR11R12, COR13, COOH, COOR14, CONR11R12, -(O)n-SOmR15; n vale 0 o 1; m vale 0, 1 o 2; o R1 y R5 representan O-fenilo, que está sin sustituir o está sustituido por de 1 a 3 sustituyentes seleccionados de entre el grupo consistente en F, Cl, Br, I, alquilo C1-4, OH, O-alquilo C1-4, NR16R17, CN o C1-4-alquil sulfonilo, que está sin sustituir o está fluorado parcial o totalmente; R16 y R17, representan H o alquilo C1-4, estando los grupos alquilo no sustituidos o fluorados total o parcialmente; R10 representa H o alquilo C1-4, sin sustituir o sustituido total o parcialmente por fluor; R11 y R12, independientemente entre sí, representan H, alquilo C1-4 que pueden estar fluorados total o parcialmente y un grupo CH2 puede estar sustituido por O o NR18; o, R11 y R12, conjuntamente representan un anillo de 5, 6 o 7 miembros; o, R1 y R12 representan COR19 o SO2R20; R18, R19 y R20, independientemente entre sí, representan H o alquilo C1-4, sin sustituir o sustituidos total o parcialmente por fluor; R13 y R14 representan alquilo C1-4, sin sustituir o sustituido total o parcialmente por fluor; R15 representa alquilo u O-alquilo C1-4, estando los grupos alquilo sin sustituir o fluorado total o parcialmente; o: R15 representa OH u NR21R22; R21 y R22 independientemente entre sí representan H o alquilo C1-4, sin sustituir o sustituido total o parcialmente por fluor, pudiendo un grupo CH2 arbitrario estar sustituido por NR23; R23 representa H o alquilo C1-4, sin sustituir o sustituido total o parcialmente por fluor; o R21 y R22 forman conjuntamente un anillo de 5, 6 o 7 miembros; pero R1 y R5 no pueden ser simultáneamente Cl o CH3; R2, R3 y R4 representan H, o una de los radicales R2, R3 o R4 puede ser F; R6, R7, R8 y R9, independientemente entre sí representan H, F, Cl, Br, I, CN, alquilo u O-alquilo C1-4 sin sustituir o sustituido total o parcialmente por fluor; o, R6, R7, R8 y R9, representan cicloalquilo C3-7, sin sustituir o parcialmente por fluor; o R6, R7, R8 y R9 representan OH, OCOR24 o NR25R26; R24 representa H o alquilo C1-4, sin sustituir o sustituido total o parcialmente por fluor; R25 y R26, independientemente entre sí representan H o C1-4, sin sustituir o sustituido total o parcialmente por fluor; o, R25 y R26 representan H o alquilo C1-4, sin sustituir o sustituido total o parcialmente por fluor; o, R25 y R26 representan COR27; o R25 y R26 conjuntamente con el átomo de nitrogeno al cual están unidos, representan un anillo de 5, 6 o 7 miembros, en el cual un grupo CH2 arbitrario puede estar reemplazado por O o por NR18; R27 representa H o alquilo C1-4, sin sustituir o sustituido total o parcialmente por fluor; como también sus sales farmacéuticamente aceptables o trifluoracetatos para la utilizacion de sustancias de la formula (1) para la preparacion de un medicamento para el tratamiento de las enfermedades que pueden ser influidas por intermedio de la inhibicion del intercambiador Na+/H+, y también se refiere a un medicamento que las contiene.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10060292A DE10060292A1 (de) | 2000-12-05 | 2000-12-05 | Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032778A1 true AR032778A1 (es) | 2003-11-26 |
Family
ID=7665784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105612A AR032778A1 (es) | 2000-12-05 | 2001-12-03 | Benzimidazoles sustituidos, y su utilizacion para la preparacion de medicamento |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US6686384B2 (es) |
| EP (1) | EP1341770B1 (es) |
| JP (1) | JP4323803B2 (es) |
| KR (1) | KR20030070045A (es) |
| CN (1) | CN1478081A (es) |
| AR (1) | AR032778A1 (es) |
| AT (1) | ATE329906T1 (es) |
| AU (1) | AU2002219135A1 (es) |
| BR (1) | BR0115936A (es) |
| CA (1) | CA2430412A1 (es) |
| CZ (1) | CZ20031538A3 (es) |
| DE (2) | DE10060292A1 (es) |
| EE (1) | EE200300193A (es) |
| HR (1) | HRP20030449A2 (es) |
| HU (1) | HUP0400967A3 (es) |
| IL (1) | IL156161A0 (es) |
| MX (1) | MXPA03004932A (es) |
| NO (1) | NO20032490L (es) |
| NZ (1) | NZ526250A (es) |
| PL (1) | PL366305A1 (es) |
| RU (1) | RU2272031C2 (es) |
| SK (1) | SK6822003A3 (es) |
| WO (1) | WO2002046169A1 (es) |
| ZA (1) | ZA200303932B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2243226C2 (ru) * | 1999-06-22 | 2004-12-27 | НьюроСёрч А/С | Новые производные бензимидазола и содержащие эти соединения фармацевтические композиции |
| US20030187045A1 (en) * | 2001-12-21 | 2003-10-02 | Uwe Heinelt | Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic |
| DE10163239A1 (de) * | 2001-12-21 | 2003-07-10 | Aventis Pharma Gmbh | Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament |
| US20050054705A1 (en) * | 2003-02-04 | 2005-03-10 | Aventis Pharma Deutschland Gmbh | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them |
| DE10304374A1 (de) * | 2003-02-04 | 2004-08-05 | Aventis Pharma Deutschland Gmbh | Neue substituierte 2-Aminoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE10304294A1 (de) * | 2003-02-04 | 2004-08-12 | Aventis Pharma Deutschland Gmbh | N-Substituierte(Benzoimidazol-2-yl)-phenyl, Verfahren zu ihrer Herstellung , ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE10341240A1 (de) * | 2003-09-08 | 2005-04-07 | Aventis Pharma Deutschland Gmbh | Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| US7470712B2 (en) * | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| GB0401334D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| WO2006078907A1 (en) * | 2005-01-20 | 2006-07-27 | Amgen Inc. | 2-substituted benzimidazole derivatives as vanilloid receptor ligands and their use in treatments |
| TWI370820B (en) * | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| CA2612922A1 (en) * | 2005-06-21 | 2006-12-28 | Neurosearch A/S | 2-(phenylamino)benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
| TWI387592B (zh) * | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
| EP2088861A4 (en) * | 2006-10-25 | 2010-07-07 | Takeda Pharmaceutical | Benzimidazole compounds |
| US20120088737A2 (en) * | 2009-10-02 | 2012-04-12 | Ajinomoto Co., Inc | Novel acyl guanidine derivatives |
| RU2012120784A (ru) * | 2009-11-12 | 2013-12-20 | Селвита С.А. | Соединение, способ его получения, фармацевтическая композиция, применение соединения, способ модулирования или регулирования сериновых/треониновых киназ и средство, модулирующее сериновые/треониновые киназы |
| US8604217B2 (en) | 2009-11-12 | 2013-12-10 | Selvita S.A. | Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
| CN102060780B (zh) * | 2010-12-27 | 2014-11-05 | 雅本化学股份有限公司 | 2-(n-取代)-氨基苯并咪唑衍生物的制备方法 |
| CN103435554A (zh) * | 2013-09-06 | 2013-12-11 | 中国药科大学 | 2-苯氨基苯并咪唑类化合物及其用途 |
| ES2732902T3 (es) * | 2014-02-11 | 2019-11-26 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Bencimidazol-2-aminas como inhibidores de MIDH1 |
| CN105061324B (zh) * | 2015-08-14 | 2017-09-12 | 广西师范大学 | 一种2‑芳基‑1,3‑二氢苯并咪唑衍生物及其合成方法和应用 |
| CN109331014B (zh) * | 2018-10-29 | 2021-06-04 | 南方医科大学南方医院 | 一种苯并咪唑衍生物在制备治疗心衰药物中的用途 |
| CN112675169A (zh) * | 2020-12-23 | 2021-04-20 | 南京景瑞康分子医药科技有限公司 | Itm-1b4在制备预防和/或治疗肿瘤药物中的应用 |
| WO2024028893A1 (en) * | 2022-08-01 | 2024-02-08 | Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) | Substituted benzimidazoles for treating viral diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1171904A (en) | 1965-10-21 | 1969-11-26 | Unilever Ltd | Anilinobenzimidazoles having Antibacterial Properties |
| RU2043344C1 (ru) * | 1991-05-20 | 1995-09-10 | Курский Государственный Медицинский Институт | N-2-(1- r1-5-r2-6-r3- бензимидазолил)сукцинаминовые кислоты, проявляющие нейролептическую, антигипоксическую и антиаритмическую активность |
| DE4328869A1 (de) | 1993-08-27 | 1995-03-02 | Hoechst Ag | Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19548812A1 (de) | 1995-12-27 | 1997-07-03 | Hoechst Ag | Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation |
| US6166219A (en) * | 1995-12-28 | 2000-12-26 | Fujisawa Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| AU717430B2 (en) | 1996-08-26 | 2000-03-23 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
-
2000
- 2000-12-05 DE DE10060292A patent/DE10060292A1/de not_active Ceased
-
2001
- 2001-11-22 EE EEP200300193A patent/EE200300193A/xx unknown
- 2001-11-22 MX MXPA03004932A patent/MXPA03004932A/es unknown
- 2001-11-22 HR HR20030449A patent/HRP20030449A2/hr not_active Application Discontinuation
- 2001-11-22 SK SK682-2003A patent/SK6822003A3/sk unknown
- 2001-11-22 RU RU2003120069/04A patent/RU2272031C2/ru not_active IP Right Cessation
- 2001-11-22 AU AU2002219135A patent/AU2002219135A1/en not_active Abandoned
- 2001-11-22 EP EP01999563A patent/EP1341770B1/de not_active Expired - Lifetime
- 2001-11-22 IL IL15616101A patent/IL156161A0/xx unknown
- 2001-11-22 HU HU0400967A patent/HUP0400967A3/hu unknown
- 2001-11-22 CN CNA018200443A patent/CN1478081A/zh active Pending
- 2001-11-22 NZ NZ526250A patent/NZ526250A/en unknown
- 2001-11-22 AT AT01999563T patent/ATE329906T1/de not_active IP Right Cessation
- 2001-11-22 BR BR0115936-4A patent/BR0115936A/pt not_active IP Right Cessation
- 2001-11-22 CZ CZ20031538A patent/CZ20031538A3/cs unknown
- 2001-11-22 WO PCT/EP2001/013586 patent/WO2002046169A1/de not_active Ceased
- 2001-11-22 CA CA002430412A patent/CA2430412A1/en not_active Abandoned
- 2001-11-22 DE DE50110181T patent/DE50110181D1/de not_active Expired - Lifetime
- 2001-11-22 JP JP2002547908A patent/JP4323803B2/ja not_active Expired - Fee Related
- 2001-11-22 PL PL01366305A patent/PL366305A1/xx not_active Application Discontinuation
- 2001-11-22 KR KR10-2003-7007467A patent/KR20030070045A/ko not_active Withdrawn
- 2001-12-03 AR ARP010105612A patent/AR032778A1/es unknown
- 2001-12-04 US US10/000,028 patent/US6686384B2/en not_active Expired - Fee Related
-
2003
- 2003-05-20 US US10/441,124 patent/US6958357B2/en not_active Expired - Fee Related
- 2003-05-21 ZA ZA200303932A patent/ZA200303932B/en unknown
- 2003-06-02 NO NO20032490A patent/NO20032490L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US6958357B2 (en) | 2005-10-25 |
| DE10060292A1 (de) | 2002-06-20 |
| EP1341770B1 (de) | 2006-06-14 |
| SK6822003A3 (en) | 2003-11-04 |
| EE200300193A (et) | 2003-08-15 |
| WO2002046169A1 (de) | 2002-06-13 |
| RU2272031C2 (ru) | 2006-03-20 |
| KR20030070045A (ko) | 2003-08-27 |
| EP1341770A1 (de) | 2003-09-10 |
| DE50110181D1 (de) | 2006-07-27 |
| NO20032490L (no) | 2003-07-22 |
| CN1478081A (zh) | 2004-02-25 |
| JP4323803B2 (ja) | 2009-09-02 |
| HUP0400967A2 (hu) | 2004-08-30 |
| JP2004517086A (ja) | 2004-06-10 |
| ATE329906T1 (de) | 2006-07-15 |
| CA2430412A1 (en) | 2002-06-13 |
| US6686384B2 (en) | 2004-02-03 |
| NO20032490D0 (no) | 2003-06-02 |
| US20020132842A1 (en) | 2002-09-19 |
| BR0115936A (pt) | 2003-10-28 |
| ZA200303932B (en) | 2004-04-15 |
| IL156161A0 (en) | 2003-12-23 |
| US20030191170A1 (en) | 2003-10-09 |
| PL366305A1 (en) | 2005-01-24 |
| HRP20030449A2 (en) | 2005-04-30 |
| CZ20031538A3 (cs) | 2003-09-17 |
| MXPA03004932A (es) | 2003-09-10 |
| AU2002219135A1 (en) | 2002-06-18 |
| NZ526250A (en) | 2004-11-26 |
| HUP0400967A3 (en) | 2004-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032778A1 (es) | Benzimidazoles sustituidos, y su utilizacion para la preparacion de medicamento | |
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| PE23196A1 (es) | Compuesto util para tratar infecciones por retrovirus | |
| MX9307940A (es) | Nuevos derivados de la imidazopiridina, proceso para su preparacion y formulaciones farmaceuticas que los incluyen | |
| AR034283A1 (es) | Compuestos heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| ES2084944T3 (es) | Amidas terapeuticas. | |
| AR070473A2 (es) | Compuestos inhibidores de la renina, un procedimiento de preparacion del compuesto, una composicion farmaceutica, uso del compuesto para preparar un medicamento y compuesto intermediario | |
| AR009938A1 (es) | Nuevos derivados de arilglicinamida, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos | |
| UY27092A1 (es) | Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen | |
| AR038476A1 (es) | Derivados de quinazolina | |
| GT199800180A (es) | Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos. | |
| ES2081187T3 (es) | Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
| PA8432901A1 (es) | Compuestos de piridilpirrol | |
| AR019053A1 (es) | Uso de 2'2'-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen | |
| AR013815A1 (es) | NUEVOS DERIVADOS DEL ACIDO 4-FORMIL-4, 4a, 5, 6, 7, 7a, 8, 8a-OCTAHIDRO- 7-METIL-3-(1-METILETIL)-1,4-METANO-S-INDACEN-3a(1H)-CARBOXILICO, UN PROCESOPARA SU PREPARACION, SU USO EN LA FABRICACION DE UN MEDICAMENTO Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE. | |
| UY28536A1 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos. | |
| AR018717A1 (es) | COMPUESTOS DERIVADOS DE PIPERIDINA, SU USO, UN PROCESO PARA SU PREPARACIoN, COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN, Y COMPUESTOS INTERMEDIARIOS. | |
| ES2118203T3 (es) | Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
| PE20040698A1 (es) | Derivados de isoindolina | |
| ES2160602T3 (es) | Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria. | |
| AR007997A1 (es) | Un derivado de distamicina sustituida con acriloilo, sus utilizaciones, un procedimiento para producirlo y una composicion farmaceutica que lo comprende. | |
| UY28357A1 (es) | Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos | |
| DK0527081T3 (da) | Hidtil ukendte substituerede 3-piperazinylalkyl-2,3-dihydro-1,3-4H-benzoxazin-4-oner, deres fremstilling og terapeutiske anvendelse | |
| AR012723A1 (es) | Derivados triptolidos utiles en el tratamiento de enfermedades autoinmunes y usos en la fabricacion de medicamentos | |
| AR011886A1 (es) | Compuestos atropisomeros de 3-heteroaril-4-(3h)-quinazolinonas y composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |